https://go.evvnt.com/1037489-0?pid=5248 Online event
Boston, MA 02110
$1899.00 - $ 3897.00
Lectures & Conferences
Following two successful virtual experiences, the 3rd JAK Inhibitors Drug Development Summit is making its way to Boston, MA warmly welcoming the JAK inhibitor community back to in-person meetings.
We are uniting this diverse community of world-leading experts from a range of therapeutic backgrounds all tied together by one thing, treating dermatologic, autoimmune, oncologic and many more inflammatory indications through JAK inhibition.
This remains the only end-to-end industry meeting committed to delivering new JAK inhibitor therapeutics to market through collaboration. This year's summit bestows an unrivaled prospect to industry experts; debating JAKi safety with benefit-risk conversations, exploring JAK selectivity to elevate precise approaches, reviewing opportunities to foray into indications of unmet need, and embracing discussion around topical/oral/alternate drug delivery methods to accelerate production of the next generation of JAK inhibitors.
Learn more, download your copy of the full event guide here: https://bit.ly/3sZOhFg
Drug Developer Pricing - Conference Only: USD 2299.00,
Drug Developer Pricing - Conference + 1 Workshop: USD 2698.00,
Drug Developer Pricing - Conference + 2 Workshops: USD 3097.00,
Academic Pricing - Conference Only: USD 1899.00,
Academic Pricing - Conference + 1 Workshop: USD 2223.00,
Academic Pricing - Conference + 2 Workshops: USD 2547.00,
Solution Provider Pricing - Conference Only: USD 2899.00,
Solution Provider Pricing - Conference + 1 Workshop: USD 3398.00,
Solution Provider Pricing - Conference + 2 Workshops: USD 3897.00
Speakers: Brett King MD, Associate Professor, Dermatology, Yale University School of Medicine, Wilma Bergfeld, MD Director of Dermatopathology Fellowship, The Cleveland Clinic, Mehdi Rashighi, MD Assistant Professor of Dermatology and Medicine, University of Massachusetts, Kendall Marcus, Director Dermatology and Dentistry, FDA, Joshua Rancourt, Director, Gastroenterology Medical Science Liaisons, Eli Lilly and Co., Jim Lee, Head Immunology and Inflammation, Incyte, David Rosmarin, MD Assistant Professor, TUFTS Medical Center, Robert Clarke, Chief Executive Officer and Co-Founder, Kinaset Therapeutics, Jim Casella, Chief Development Officer, Concert Pharmaceuticals, Patrick Burnett, Senior Vice President and Chief Medical Officer, Arcutis Therapeutics, Chris de Savi, Senior Vice President and Head of Drug Discovery, Kymera Therapeutics, William Damsky, MD Dermatologist, Yale New Haven Hospital, Cedric Hubeau, Immunology/Autoimmunology Head, Kymera Therapeutics, Min Jae Song, Senior Scientist, NIH/NCATS, Gary Krishnan, Senior Research Fellow Medical, Eli Lilly and Co., Ruth Ann Vleugels, Vice Chair of Academic Affairs, Brigham and Women’s Hospital Department of Dermatology